Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07303712 · ClinicalTrials.gov registry record

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

A clinical trial of Hepatocellular Carcinoma (HCC), sponsored by Palo Alto Veterans Institute for Research.

Recruiting
Registry status
12
Enrollment target
1
Study location

NCT07303712: Recruiting study of Hepatocellular Carcinoma (HCC), sponsored by Palo Alto Veterans Institute for Research.

NCT07303712 is a study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 12 participants, below the 350-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07303712, a study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Palo Alto Veterans Institute for Research.

RECRUITING
Registry status
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Primary Outcome

blood samples

Conditions Studied

Hepatocellular Carcinoma (HCC)

Study Locations (1)

California

  • VA Palo Alto Health Care System - Palo Alto

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-08-01
Est. Completion 2026-12-01
Palo Alto Veterans Institute for Research

35 total trials

What NCT07303712 shows while recruiting

NCT07303712 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 350-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 0 interventions.

NCT07303712 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07303712 about?

NCT07303712 is a clinical study titled "Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90". The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinom...

What is the current status of trial NCT07303712?

This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2024-08-01. Estimated completion is 2026-12-01.

What conditions does trial NCT07303712 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).

Who is sponsoring clinical trial NCT07303712?

This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07303712 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma (HCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07303712's enrollment target sits among peer trials

12 16th of 15 the lowest of 15 other Hepatocellular Carcinoma (HCC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatocellular Carcinoma (HCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07303712

Source: ClinicalTrials.gov NCT07303712, the US trial registry maintained by the National Library of Medicine. NCT07303712 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.